Category: Top Story
-
Fair Isaac shares drop after Equifax unveils lower VantageScore pricing
Fair Isaac Corp. (NYSE:FICO) shares fell 3.2% in premarket trading Wednesday after Equifax announced competitive pricing for its VantageScore 4.0 credit scoring service. Equifax said it will offer mortgage credit scores through VantageScore 4.0 at $4.50 per score until the end of 2027, a move seen as a direct challenge to the long-dominant FICO credit…
-
AlphaTON shares surge 200% after unveiling digital asset-powered oncology initiative
Shares of AlphaTON Capital Corp (NASDAQ:ATON) soared 200% on Wednesday after the company announced plans to explore the tokenization of its mesothelioma treatment program, marking a first-of-its-kind effort to merge blockchain technology with oncology innovation. The company said it has signed a non-binding letter of intent to evaluate tokenizing the single-indication economics of its TT-4…
-
TopBuild acquires Specialty Products and Insulation in $1 billion all-cash deal
TopBuild Corp (NYSE:BLD) has completed the $1 billion acquisition of Specialty Products and Insulation (SPI) in an all-cash transaction aimed at strengthening its specialty distribution business and expanding its footprint in the commercial and industrial markets. The deal, which closed on October 7, was financed entirely with cash on hand, including proceeds from a senior…
-
AST SpaceMobile shares surge after securing commercial deal with Verizon
Shares of AST SpaceMobile (NASDAQ:ASTS) jumped 7% on Wednesday after the company announced it had signed a definitive commercial agreement with Verizon (NYSE:VZ) to deliver space-based cellular broadband service across the continental United States. Under the agreement, AST SpaceMobile will begin providing direct-to-device connectivity for Verizon customers using standard smartphones starting in 2026. The deal…
-
Karyopharm shares slide after unveiling $100 million financing package
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) fell 13% on Wednesday after the commercial-stage biopharmaceutical company announced a set of strategic financing transactions designed to provide $100 million in additional liquidity and capital resources. The Newton, Massachusetts-based firm said the new financing will extend its cash runway into the second quarter of 2026. The transactions, expected to…
-
NANO Nuclear shares drop after unveiling $400 million private placement
Shares of NANO Nuclear Energy Inc. (NASDAQ:NNE) fell 9% on Wednesday after the advanced nuclear technology firm announced a $400 million private placement of its common stock. The company said it has entered into securities purchase agreements with institutional investors for 8,490,767 shares in an oversubscribed offering priced at market value under Nasdaq rules. The…
-
QuantumScape shares climb after partnership with Murata on battery components
Shares of QuantumScape (NYSE:QS) rose 7% on Wednesday after the solid-state battery developer announced a joint development agreement with Murata Manufacturing to advance the production of ceramic separators used in its next-generation batteries. The partnership is designed to accelerate high-volume manufacturing of ceramic separators, a key element of QuantumScape’s solid-state battery architecture. The agreement builds…
-
Cenovus posts stronger-than-expected Q3 production results
Cenovus Energy (NYSE:CVE) reported preliminary third-quarter upstream production of around 832,000 barrels of oil equivalent per day (boe/d), surpassing analyst expectations of 821,148 boe/d. Output from the company’s oil sands operations came in at approximately 640,000 boe/d, while downstream production averaged about 712,000 boe/d during the quarter. Cenovus said that its key growth projects remain…
-
Zenas Biopharma Acquires Rights to Three Autoimmune Drug Candidates from InnoCare
Zenas Biopharma (NASDAQ:ZBIO) has entered into a licensing agreement with InnoCare Pharma (USOTC:INCPF), securing global rights to three autoimmune disease candidates from InnoCare’s development portfolio. The collaboration includes orelabrutinib, a BTK inhibitor currently in Phase 3 clinical trials for the treatment of multiple sclerosis. Additionally, the deal grants Zenas access to two early-stage assets —…
-
Equinor’s Third-Quarter Update Misses Market Expectations
Equinor (NYSE:EQNR) posted its third-quarter trading update on Wednesday, coming in roughly 5% below consensus estimates for adjusted operating income after tax, which had been forecast at $1.8 billion. In its Exploration & Production (E&P) Norway division, the company reported realized liquids prices between $67.2 and $69.2 per barrel, up from $65.4 in the previous…